Dysregulation of lncRNA-H19 in cardiometabolic diseases and the molecular mechanism involved : a systematic review

References

• Sinclair AJ, Abdelhafiz AH. Cardiometabolic disease in the older person: prediction and prevention for the generalist physician. Cardiovasc Endocrinol Metab. 2020;9(3):90–95.
   PubMed Web of Science ®Google Scholar
• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases writing group. global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Saeedi P, Kaundal A, et al. Diabetes and global ageing among 65–99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2020;162:108078.
   PubMed Web of Science ®Google Scholar
• Agostinis-Sobrinho C, Gómez-Martínez S, Nova E, et al. Lifestyle patterns and endocrine, metabolic, and immunological biomarkers in European adolescents: the HELENA study. Pediatr Diabetes. 2019;20(1):23–31.
   PubMed Web of Science ®Google Scholar
• Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol. 2019;15(6):327–345.
   PubMed Web of Science ®Google Scholar
• Stols-Gonçalves D, Tristão LS, Henneman P, et al. Epigenetic markers and microbiota/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease. Curr Diab Rep. 2019;19(6):31.
   PubMed Web of Science ®Google Scholar
• Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab. 2019;29(5):1028–1044.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Du W, Yang B. Long non-coding RNAs as new regulators of cardiac electrophysiology and arrhythmias: molecular mechanisms, therapeutic implications and challenges. Pharmacol Ther. 2019;203:107389.
   PubMed Web of Science ®Google Scholar
• Han Y, Ma J, Wang J, et al. Silencing of H19 inhibits the adipogenesis and inflammation response in ox-LDL-treated Raw264.7 cells by up-regulating miR-130b. Mol Immunol. 2018;93:107–114.
   PubMed Web of Science ®Google Scholar
• Razavi ZS, Tajiknia V, Majidi S, et al. Gynecologic cancers and non-coding RNAs: epigenetic regulators with emerging roles. Crit Rev Oncol Hematol. 2021;157:103192.
   PubMed Web of Science ®Google Scholar
• Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–1789.
   PubMed Web of Science ®Google Scholar
• Hashemipour M, Boroumand H, Mollazadeh S, et al. Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers. Gynecol Oncol. 2021;161(1):314–327.
   PubMed Web of Science ®Google Scholar
• Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–914.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689–693.
   PubMed Web of Science ®Google Scholar
• Nagano T, Mitchell JA, Sanz LA, et al. The air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science. 2008;322(5908):1717–1720.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Abdelmohsen K, Srikantan S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47(4):648–655.
   PubMed Web of Science ®Google Scholar
• Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3ʹ UTRs via Alu elements. Nature. 2011;470(7333):284–288.
   PubMed Web of Science ®Google Scholar
• Kallen AN, Zhou XB, Xu J, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52(1):101–112.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Hamblin MR. Regulation of Glycolysis by Non-coding RNAs in Cancer: switching on the Warburg Effect. Mol Ther Oncolytics. 2020;19:218–239.
   PubMed Web of Science ®Google Scholar
• Pielok A, Marycz K. Non-Coding RNAs as potential novel biomarkers for early diagnosis of hepatic insulin resistance. Int J Mol Sci. 2020;21(11):4182.
   PubMed Web of Science ®Google Scholar
• Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays. 2010;32(6):473–480.
   PubMed Web of Science ®Google Scholar
• Brannan CI, Dees EC, Ingram RS, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990;10(1):28–36.
   PubMed Web of Science ®Google Scholar
• Noale M, Limongi F, Maggi S. Epidemiology of Cardiovascular Diseases in the Elderly. Adv Exp Med Biol. 2020;1216:29–38.
   PubMed Web of Science ®Google Scholar
• Goradel NH, Hour FG, Negahdari B, et al. Stem cell therapy: a new therapeutic option for cardiovascular diseases. J Cell Biochem. 2018;119(1):95–104.
   PubMed Web of Science ®Google Scholar
• Wang XM, Li XM, Song N, et al. Long non-coding RNAs H19, MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction. Biomed Pharmacother. 2019;118:109208.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Li T, Xiao H, et al. LncRNA-H19 drives cardiomyocyte senescence by targeting miR-19a/socs1/p53 Axis. Front Pharmacol. 2021;12:631835.
   PubMed Web of Science ®Google Scholar
• Huang ZW, Tian LH, Yang B, et al. Long noncoding RNA H19 acts as a competing endogenous RNA to mediate ctgf expression by sponging miR-455 in cardiac fibrosis. DNA Cell Biol. 2017;36(9):759–766.
   PubMed Web of Science ®Google Scholar
• Xiong G, Jiang X, Song T. The overexpression of lncRNA H19 as a diagnostic marker for coronary artery disease. Rev Assoc Med Bras (1992). 2019;65(2):110–117.
   PubMed Web of Science ®Google Scholar
• Kobiyama K, Ley K. Atherosclerosis. Circ Res. 2018;123(10):1118–1120.
   PubMed Web of Science ®Google Scholar
• Lee H, Han S, Kwon CS, et al. Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein Cell. 2016;7(2):100–113.
   PubMed Web of Science ®Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410–1422.
   PubMed Web of Science ®Google Scholar
• Cao T, Jiang Y, Li D, et al. H19/TET1 axis promotes TGF-β signaling linked to endothelial-to-mesenchymal transition. Faseb J. 2020;34(6):8625–8640.
   PubMed Web of Science ®Google Scholar
• Satoh M, Tabuchi T, Minami Y, et al. Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal. Immunobiology. 2012;217(5):533–539.
   PubMed Web of Science ®Google Scholar
• Wu MY, Li CJ, Hou MF, et al. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 2017;18(1):10.
   Google Scholar
• Yang Y, Lv J, Jiang S, et al. The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death Dis. 2016;7(5):e2234.
   PubMed Web of Science ®Google Scholar
• Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 2014;92(1):73–89.
   PubMed Web of Science ®Google Scholar
• Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005;11(23):3061–3072.
   PubMed Web of Science ®Google Scholar
• Han Y, Dong B, Chen M, et al. LncRNA H19 suppresses pyroptosis of cardiomyocytes to attenuate myocardial infarction in a PBX3/CYP1B1-dependent manner. Mol Cell Biochem. 2021;476(3):1387–1400.
   PubMed Web of Science ®Google Scholar
• Gao W, Zhu M, Wang H, et al. Association of polymorphisms in long non-coding RNA H19 with coronary artery disease risk in a Chinese population. Mutat Res. 2015;772:15–22.
   PubMed Web of Science ®Google Scholar
• Safaei S, Tahmasebi-Birgani M, Bijanzadeh M, et al. Increased Expression Level of Long Noncoding RNA H19 in Plasma of Patients with Myocardial Infarction. Int J Mol Cell Med. 2020;9(2):122–129.
   PubMed Web of Science ®Google Scholar
• Huang J, Yang J, Li J, et al. Association of long noncoding RNA H19 polymorphisms with the susceptibility and clinical features of ischemic stroke in southern Chinese Han population. Metab Brain Dis. 2019;34(4):1011–1021.
   PubMed Web of Science ®Google Scholar
• Bitarafan S, Yari M, Broumand MA, et al. Association of increased levels of lncRNA H19 in PBMCs with risk of coronary artery disease. Cell J. 2019;20(4):564–568.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao W, Long QQ, et al. Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep. 2017;7(1):7491.
   PubMed Web of Science ®Google Scholar
• Li L, Xie J, Zhang M, et al. Homocysteine harasses the imprinting expression of IGF2 and H19 by demethylation of differentially methylated region between IGF2/H19 genes. Acta Biochim Biophys Sin (Shanghai). 2009;41(6):464–471.
   PubMed Web of Science ®Google Scholar
• Han DK, Khaing ZZ, Pollock RA, et al. H19, a marker of developmental transition, is reexpressed in human atherosclerotic plaques and is regulated by the insulin family of growth factors in cultured rabbit smooth muscle cells. J Clin Invest. 1996;97(5):1276–1285.
   PubMed Web of Science ®Google Scholar
• Huang J, Li M, Li J, et al. LncRNA H19 rs4929984 variant is associated with coronary artery disease susceptibility in Han Chinese female population. Biochem Genet. 2021. DOI:10.1007/s10528-021-10055-w.
   Web of Science ®Google Scholar
• Jun JI, Lau LF. Resolution of organ fibrosis. J Clin Invest. 2018;128(1):97–107.
   PubMed Web of Science ®Google Scholar
• Park S, Nguyen NB, Pezhouman A, et al. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019;209:121–137.
   PubMed Web of Science ®Google Scholar
• Creemers EE, van Rooij E. Function and therapeutic potential of noncoding RNAs in cardiac fibrosis. Circ Res. 2016;118(1):108–118.
   PubMed Web of Science ®Google Scholar
• Grimaldi V, De Pascale MR, Zullo A, et al. Evidence of epigenetic tags in cardiac fibrosis. J Cardiol. 2017;69(2):401–408.
   PubMed Web of Science ®Google Scholar
• Tao H, Cao W, Yang JJ, et al. Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. Cardiovasc Pathol. 2016;25(5):381–389.
   PubMed Web of Science ®Google Scholar
• Morgoulis D, Berenstein P, Cazacu S, et al. sPIF promotes myoblast differentiation and utrophin expression while inhibiting fibrosis in Duchenne muscular dystrophy via the H19/miR-675/let-7 and miR-21 pathways. Cell Death Dis. 2019;10(2):82.
   PubMedGoogle Scholar
• Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227(2):493–507.
   PubMed Web of Science ®Google Scholar
• Topkara VK, Mann DL. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther. 2011;25(2):171–182.
   PubMed Web of Science ®Google Scholar
• Omura J, Habbout K, Shimauchi T, et al. Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension. Circulation. 2020;142(15):1464–1484.
   PubMed Web of Science ®Google Scholar
• Choong OK, Chen CY, Zhang J, et al. Hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction. Theranostics. 2019;9(22):6550–6567.
   PubMed Web of Science ®Google Scholar
• Skinner JR, Winbo A, Abrams D, et al. Channelopathies that lead to sudden cardiac death: clinical and genetic aspects. Heart Lung Circ. 2019;28(1):22–30.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
   PubMed Web of Science ®Google Scholar
• Wang H, Cao Y, Shu L, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med. 2020;24(2):1399–1412.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu R, Li X, et al. Long Noncoding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia. Hepatology. 2019;70(5):1658–1673.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Dhaouadi I, Gaziano I, et al. LincRNA H19 protects from dietary obesity by constraining expression of monoallelic genes in brown fat. Nat Commun. 2018;9(1):3622.
   PubMedGoogle Scholar
• Gui W, Zhu WF, Zhu Y, et al. LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1. Cell Commun Signal. 2020;18(1):173.
   PubMed Web of Science ®Google Scholar
• Liu J, Tang T, Wang GD, et al. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease. Biosci Rep. 2019;39:7.
   Web of Science ®Google Scholar
• Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidemia and NAFLD. Nat Rev Endocrinol. 2017;13(1):36–49.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang Z, Wu J, et al. Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis. Hepatology. 2018;67(5):1768–1783.
   PubMed Web of Science ®Google Scholar
• Zhu J, Luo Z, Pan Y, et al. H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-β signaling in both hepatic stellate cells and hepatocytes. J Cell Physiol. 2019;234(6):9698–9710.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
   PubMed Web of Science ®Google Scholar
• Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162–171.
   PubMed Web of Science ®Google Scholar
• Song Y, Liu C, Liu X, et al. H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule. Hepatology. 2017;66(4):1183–1196.
   PubMed Web of Science ®Google Scholar
• Liu R, Li X, Zhu W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology. 2019;70(4):1317–1335.
   PubMed Web of Science ®Google Scholar
• Zhou D, Liu Y. Renal fibrosis in 2015: understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016;12(2):68–70.
   PubMed Web of Science ®Google Scholar
• Jiang X, Ning Q. The mechanism of lncRNA H19 in fibrosis and its potential as novel therapeutic target. Mech Ageing Dev. 2020;188:111243.
   PubMed Web of Science ®Google Scholar
• Xie H, Xue JD, Chao F, et al. Long non-coding RNA-H19 antagonism protects against renal fibrosis. Oncotarget. 2016;7(32):51473–51481.
   PubMedGoogle Scholar
• Zhu Z, Cui Y, Huang F, et al. Long non-coding RNA H19 promotes osteogenic differentiation of renal interstitial fibroblasts through Wnt-β-catenin pathway. Mol Cell Biochem. 2020;470(1–2):145–155.
   PubMed Web of Science ®Google Scholar
• Xu J, Ge T, Zhou H, et al. Absence of Long Noncoding RNA H19 Promotes Childhood Nephrotic Syndrome through Inhibiting ADCK4 Signal. Med Sci Monit. 2020;26:e922090.
   PubMed Web of Science ®Google Scholar
• Yermalovich AV, Osborne JK, Sousa P, et al. Lin28 and let-7 regulate the timing of cessation of murine nephrogenesis. Nat Commun. 2019;10(1):168.
   PubMedGoogle Scholar
• Okuyan HM, Dogan S, Terzi MY, et al. Association of serum lncRNA H19 expression with inflammatory and oxidative stress markers and routine biochemical parameters in chronic kidney disease. Clin Exp Nephrol. 2021;25(5):522–530.
   PubMed Web of Science ®Google Scholar
• Goyal N, Sivadas A, Shamsudheen KV, et al. RNA sequencing of db/db mice liver identifies lncRNA H19 as a key regulator of gluconeogenesis and hepatic glucose output. Sci Rep. 2017;7(1):8312.
   PubMedGoogle Scholar
• Goyal N, Tiwary S, Kesharwani D, et al. Long non-coding RNA H19 inhibition promotes hyperglycemia in mice by upregulating hepatic FoxO1 levels and promoting gluconeogenesis. J Mol Med (Berl). 2019;97(1):115–126.
   PubMed Web of Science ®Google Scholar
• Zhang N, Geng T, Wang Z, et al. Elevated hepatic expression of H19 long noncoding RNA contributes to diabetic hyperglycemia. JCI Insight. 2018;3(10):10.
   Web of Science ®Google Scholar
• Fawzy MS, Abdelghany AA, Toraih EA, et al. Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes but not with diabetic retinopathy: a preliminary study. Bosn J Basic Med Sci. 2020;20(3):365–371.
   PubMed Web of Science ®Google Scholar
• Nilsson E, Matte A, Perfilyev A, et al. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. J Clin Endocrinol Metab. 2015;100(11):E1491–501.
   PubMed Web of Science ®Google Scholar
• Deng J, Mueller M, Geng T, et al. H19 lncRNA alters methylation and expression of Hnf4α in the liver of metformin-exposed fetuses. Cell Death Dis. 2017;8(12):e3175.
   PubMedGoogle Scholar
• Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A. 2003;100(7):4012–4017.
   PubMed Web of Science ®Google Scholar
• Ghaedi H, Zare A, Omrani MD, et al. Genetic variants in long noncoding RNA H19 and MEG3 confer risk of type 2 diabetes in an Iranian population. Gene. 2018;675:265–271.
   PubMed Web of Science ®Google Scholar
• Tello-Flores VA, Valladares-Salgado A, Ramírez-Vargas MA, et al. Altered levels of MALAT1 and H19 derived from serum or serum exosomes associated with type-2 diabetes. Noncoding RNA Res. 2020;5(2):71–76.
   PubMed Web of Science ®Google Scholar
• Alfaifi M, Verma AK, Alshahrani MY, et al. Assessment of cell-free long non-coding RNA-H19 and miRNA-29a, miRNA-29b expression and severity of diabetes. Diabetes Metab Syndr Obes. 2020;13:3727–3737.
   PubMed Web of Science ®Google Scholar
• Massart J, Sjögren RJO, Lundell LS, et al. Altered miR-29 expression in type 2 diabetes influences glucose and lipid metabolism in skeletal muscle. Diabetes. 2017;66(7):1807–1818.
   PubMed Web of Science ®Google Scholar
• Huang M, Zhong Z, Lv M, et al. Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma. Oncotarget. 2016;7(30):47186–47200.
   PubMedGoogle Scholar
• Lv M, Zhong Z, Huang M, et al. lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1887–1899.
   PubMed Web of Science ®Google Scholar
• Gao Y, Wu F, Zhou J, et al. The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res. 2014;42(22):13799–13811.
   PubMed Web of Science ®Google Scholar
• Geng T, Liu Y, Xu Y, et al. H19 lncRNA promotes skeletal muscle insulin sensitivity in part by targeting AMPK. Diabetes. 2018;67(11):2183–2198.
   PubMed Web of Science ®Google Scholar
• Zhang BF, Jiang H, Chen J, et al. LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. J Cell Mol Med. 2020;24(1):1099–1115.
   PubMed Web of Science ®Google Scholar
• Luo R, Li L, Hu YX, et al. LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression. Kaohsiung J Med Sci. 2021;37(2):101–110.
   PubMed Web of Science ®Google Scholar
• Luo R, Xiao F, Wang P, et al. lncRNA H19 sponging miR-93 to regulate inflammation in retinal epithelial cells under hyperglycemia via XBP1s. Inflamm Res. 2020;69(3):255–265.
   PubMed Web of Science ®Google Scholar